Professor Layton joined Imperial College in 2000 as Consultant Haematologist and Honorary Reader and is Clinical Lead for Red Cell Haematology at Imperial College Healthcare NHS Trust. He is Clinical Director of the North West London Sickle Cell and Thalassaemia Network and Specialty Lead for the North West London NIHR Clinical Research Network. His clinical and research interests span the treatment and pathophysiology of red cell disorders and reflect a longstanding interest in sickle cell disease, thalassaemia and rare inherited anaemias. He is Chief/Principal investigator on several early and pivotal clinical trials of novel disease modifiers that include a first-in-class allosteric activator of red cell pyruvate kinase. He was project lead for haemolytic anaemia on the NIHR Rare Disease Translational Research Collaboration and as co-chair of the red cell multidisciplinary team (MDT) supports the NIHR BioResource Rare Disease programme. His external activities have included UK NEQAS Special Scientific Advisory Group, Medical Research Council, UK Forum on Haemoglobin Disorders, National Confidential Enquiry into Counselling for Genetic Disorders, Royal College of Obstetricians and Gynaecologists, British Paediatric Survellance Unit and British Society for Haematology steering group or committee membership. He is Medical Advisor to the Sickle Cell Society.
et al., 2022, Voxelotor in sickle cell disease, American Journal of Hematology, Vol:97, ISSN:0361-8609, Pages:830-832
et al., 2022, Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia, American Journal of Hematology, Vol:97, ISSN:0361-8609, Pages:237-238
et al., 2022, Venous cerebral blood flow quantification and cognition in patients with sickle cell anemia, Journal of Cerebral Blood Flow and Metabolism, ISSN:0271-678X
et al., 2021, Sickle cell disease patients in two London trusts: Genotyping including RH variants, Transfusion Medicine, ISSN:0958-7578
et al., 2022, Retrospective analysis of the burden of vaso-occlusive events experienced by sickle cell disease (SCD) patients in the integrated health and social care system in North West London, WILEY, Pages:130-131, ISSN:0007-1048